Indivumed Therapeutics

At Indivumed, we believe that the quality of biospecimens and the resulting data are essential for revealing all critical aspects of cancer. Therefore, we implement numerous detailed standard operating procedures (SOPs) in the collection and processing of our diverse biospecimens, achieving an ischemia time for tissue of 10-12 minutes. Nina Gabelia, our VP Global Clinical Network Operations, gets to the point: "Our goal is to preserve tissue as it exist in vivo. The most important thing is to do this in a standardized way." Our latest research study highlights the importance of rapid tissue sample processing for novel therapeutic discovery. Explore the full paper published in Cell Death & Disease: https://lnkd.in/enVPF-tg #cancerresearch #oncology #precisionmedicine #biotech

We are grateful for the opportunity to have our Founder and CEO, Prof. Dr. Hartmut Juhl, participate in the panel titled "I Have a Dream - AI for Drug Discovery" at BIO-Europe. It was a great pleasure to join such experienced industry representatives in the scientific field and engage in meaningful conversations about the future of AI in drug discovery.   A big thank you to everyone who participated and contributed to this enriching discussion, including Maria Luisa Pineda, PhD. (Envisagenics), Lovisa Afzelius (Flagship Pioneering), Stephan Brock (Molecular Health), Michelle Chen (Insilico Medicine), Tim James (Evotec), Nikolaus Krall (Exscientia) and Rogier Rooswinkel (Forbion). #BIOEurope #AIforDrugDiscovery #BiotechInnovation #Indivumed

𝗚𝗿𝗲𝗲𝘁𝗶𝗻𝗴𝘀 𝗳𝗿𝗼𝗺 𝗦𝘁𝗼𝗰𝗸𝗵𝗼𝗹𝗺! The Indivumed team is on-site at Bio-Europe 2024, engaging with industry leaders, exploring and sharing the latest innovations in cancer research and drug discovery. 📍We are excited to be at 𝗕𝗼𝗼𝘁𝗵 𝗡𝗼. 𝟰𝟬, where we are presenting our 𝗗𝗮𝘁𝗮-𝗗𝗿𝗶𝘃𝗲𝗻 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝘁𝗼 𝗡𝗼𝘃𝗲𝗹 𝗧𝗮𝗿𝗴𝗲𝘁𝘀 𝗶𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆. Make sure to stop by and say hello! ➡ And don't miss our 𝗽𝗮𝗻𝗲𝗹 𝗽𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝘁𝗶𝗼𝗻 𝘁𝗼𝗱𝗮𝘆 (𝗡𝗼𝘃. 𝟱) 𝗮𝘁 𝟰 𝗽𝗺 𝗶𝗻 𝗥𝗼𝗼𝗺 𝗞𝟭! #BioEurope2024 #CancerResearch #DrugDiscovery #Indivumed #Networking #Oncology

𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝗶𝘀 𝗟𝘂𝗻𝗴 𝗖𝗮𝗻𝗰𝗲𝗿 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗠𝗼𝗻𝘁𝗵. Our hearts go out to all lung cancer patients worldwide battling this disease. At Indivumed, we use this month to emphasize the vital role of research in improving outcomes for lung cancer patients. We are dedicated to advancing oncology cancer research by unraveling the molecular reality of cancer to achieve the promise of precision medicine for everyone. Last year, at ESMO 2023, our poster highlighted how spatial transcriptomics combined with bulk RNA-Seq offers unparalleled insights into NSCLC. Our team analyzed fresh-frozen NSCLC tumor and normal samples and showed that the combination of both datasets not only refines target expression cell types (e.g. primary tumor or immune system) but also provides a strong indicator for target gene expression variability within patients' tumors for improved precision medicine approaches. As we honor Lung Cancer Awareness Month, we invite you to explore our study findings and download the poster: https://lnkd.in/e5Kj5tey #LungCancerAwareness #PrecisionMedicine #CancerResearch #Indivumed

𝗝𝗼𝗶𝗻 𝘁𝗵𝗲 𝗣𝗮𝗻𝗲𝗹 𝗗𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 𝘄𝗶𝘁𝗵 𝗼𝘂𝗿 𝗖𝗘𝗢 𝗣𝗿𝗼𝗳. 𝗗𝗿. 𝗛𝗮𝗿𝘁𝗺𝘂𝘁 𝗝𝘂𝗵𝗹 𝗮𝘁 𝗕𝗶𝗼-𝗘𝘂𝗿𝗼𝗽𝗲 We are excited to have our Founder and CEO, Prof. Dr. Hartmut Juhl, participate in the panel discussion titled "I Have a Dream" - AI for Drug Discovery at Bio-Europe 2024. 📅 𝗗𝗮𝘁𝗲: Tuesday, November 5, 2024 📍 𝗟𝗼𝗰𝗮𝘁𝗶𝗼𝗻: Room K1 🕒 𝗧𝗶𝗺𝗲: 4 p.m. – 5 p.m. CET Together with industry experts, Prof. Dr. Hartmut Juhl will discuss how AI algorithms are reshaping the landscape and accelerating the identification and development of novel therapeutics. Learn about the latest advancements, challenges, and promising opportunities in this frontier of innovation. #BioEurope2024 #AI #DrugDiscovery #PanelDiscussion #Indivumed #Innovation #Oncology

Our latest research study highlights the importance of rapid tissue sample processing time for novel therapeutic discovery. Explore the findings in our slideshow, and read the full paper in Cell Death & Disease for the full story: https://lnkd.in/enVPF-tg

Thank you, Labiotech.eu, for sharing our latest article, and for our ongoing collaboration. 

We will be present at 𝗕𝗶𝗼-𝗘𝘂𝗿𝗼𝗽𝗲 𝟮𝟬𝟮𝟰 in Stockholm, one of Europe’s leading life sciences partnering conferences! Connect with us on-site and join also our panel discussion titled "I Have a Dream" - AI for Drug Discovery. 📅 November 4-6, 2024 | Stockholm, Sweden 📍 Booth No. 40 🎤 "I Have a Dream" - AI for Drug Discovery | November 5, 4 pm Take the chance to engage with our team, including Prof. Dr. Hartmut Juhl, Hans Vanhooren, PhD, Dr. Sachli Zafari and Kristin Maack. Learn about our 𝗗𝗮𝘁𝗮-𝗗𝗿𝗶𝘃𝗲𝗻 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵 𝘁𝗼 𝗡𝗼𝘃𝗲𝗹 𝗧𝗮𝗿𝗴𝗲𝘁𝘀 𝗶𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 and explore collaboration opportunities. See you in Stockholm! ➡️ Find out more about Bio-Europe: https://lnkd.in/dnuNZ2D ✅ 𝗔𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗕𝗶𝗼-𝗘𝘂𝗿𝗼𝗽𝗲 𝗳𝗼𝗿 𝘀𝘂𝗿𝗲? Connect with us through PartneringONE to schedule meetings and learn more about our work: https://lnkd.in/dSh2WhAN #BioEurope2024 #CancerResearch #DrugDiscovery #Oncology #DataDriven

October is Breast Cancer Awareness Month – a time to highlight the ongoing fight against breast cancer and the importance of research in improving patient outcomes. At Indivumed, we're dedicated to advancing breast cancer research. We use the highest quality tissue samples, combined with detailed clinical information, to get as close to the molecular reality of cancer as possible and deliver on the promise of precision medicine for all. Our recent study, published in Biology Direct, focuses on the molecular characterization of a rare breast cancer subtype, offering key insights into its potential resistance mechanisms and immune landscape. With findings like a mutation in the TP53 gene and evidence of endocrine resistance due to IGF1R gene amplification, our research highlights the complexity of breast cancer and the need for personalized approaches to treatment and monitoring. As we honor this important month, we invite you to explore how molecular insights like these can lead to better outcomes for patients everywhere. Read the full paper here: https://lnkd.in/eg46uPj8 Head also to the Indivumed Omics Hub to learn more about our other collaborative breast cancer research projects: https://lnkd.in/eszY_HdJ #BreastCancerAwarenessMonth #BreastCancerResearch #PrecisionMedicine #Multiomics #Oncology

Our latest publication highlights the critical impact of sample processing time to ensure reliable data for novel target discovery. Do you want to explore the key parameters of our study? ➡️ 1,800 cases (tumor and matching normal samples) of four solid tumor types analyzed. 🧬 Gene expression, proteins, and phosphoproteins compared in samples with different cold ischemia times (time it takes to preserve tissue). ⏱️ Significant differences emerged in samples frozen in just 10 minutes compared with longer cold ischemia times. 📉 Variability in molecular data becomes more pronounced the longer the delay before freezing, especially for phosphoproteins. The takeaway? Fast sample processing leads to meaningful samples with high accuracy of data for uncovering real biology and to identify novel therapeutic targets, which are otherwise not visible as differentially expressed proteins or falsely expressed. This research reinforces our commitment to our founder and CEO Prof. Dr. Hartmut Juhl’s vision of getting as close to the molecular reality of cancer as possible in order to discover genuine targets for novel oncology drug discovery. 📖 Read the full paper in Cell Death & Disease to learn more: https://lnkd.in/enVPF-tg #cancerresearch #precisionmedicine #oncology #biotechnology